Pro‐ and Anti‐Inflammatory Responses and Clinical Outcomes in Critically Ill Patients With Endotheliopathy: A Cohort Study
Acta Anaesthesiologica Scandinavica · 2025
DOI: 10.1111/aas.70117 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Acta Anaesthesiologica Scandinavica, 2025. Verfasst von Caroline Humble und 6 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Anaesthesiological Research, Department of Anaesthesiology, Zealand University Hospital, Køge, Denmark. Hauptthemen laut MEDLINE: Critical Illness, Multiple Organ Failure, Inflammation. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Greater Copenhagen Health Science Partners, Region Zealand Health Science Research Fund, Clinical Academic Group (CAG) Center for Endotheliomics.
Abstract (Originalsprache)
Background
Multiple organ dysfunction syndrome (MODS) in critical illness involves dysregulated immune and inflammatory responses, endotheliopathy, and coagulation activation. We investigated how three types of endotheliopathy biomarkers relate to pro‐ and anti‐inflammatory responses and clinical outcomes in intensive care unit (ICU) patients.
Methods
In this secondary, explorative analysis of a prospective single‐centre cohort ( n = 459), we assessed associations between endotheliopathy biomarkers (syndecan‐1, soluble thrombomodulin (sTM), platelet endothelial cell adhesion molecule‐1 (PECAM‐1)) and inflammatory biomarkers (pro‐inflammatory: IFN‐ϒ, IL‐1β, IL‐2, IL‐6, IL‐8, IL‐12p70, TNF‐α; anti‐inflammatory: IL‐4, IL‐10, IL‐13) at ICU admission using linear regression. Associations with 30‐day clinical outcomes were analysed using linear and Cox regression. All models were adjusted for age, sex, septic shock, pre‐ICU surgery and chronic disease.
Results
Higher levels of all three endotheliopathy biomarkers were associated with higher levels of inflammatory biomarkers. PECAM‐1, however, showed no significant association with IFN‐ϒ, IL‐1β and IL‐12p70. IL‐4 was excluded from linear regression due to > 50% imputed values. Higher levels of all three endotheliopathy biomarkers were significantly associated with increased mean and maximum modified Sequential Organ Failure Assessment (mSOFA) scores over 30 days, as well as with renal, hepatic, and coagulation failure, and 30‐day all‐cause mortality. Only sTM was significantly associated with cardiovascular failure; none were significantly associated with respiratory failure. Higher levels of sTM were associated with the highest levels of inflammatory biomarkers, the largest increases in mean and maximum mSOFA scores, and the highest hazard ratios for organ failure and 30‐day all‐cause mortality, compared with syndecan‐1 and PECAM‐1.
Conclusion
In this cohort of critically ill ICU patients, endotheliopathy was associated with (1) higher levels of pro‐ and anti‐inflammatory biomarkers at ICU admission and (2) MODS, single organ failure, and 30‐day all‐cause mortality. Among the three endotheliopathy biomarkers, sTM demonstrated the most consistent and strongest associations with both inflammatory biomarkers and clinical outcomes. These findings are exploratory and should be interpreted as hypothesis‐generating. Editor's Comment In this analysis of different biomarkers in a critically ill cohort, associations are demonstrated between markers related to endothelial stress, cytokines related to modulation of inflammation, and severity of illness scores.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Centre for Anaesthesiological Research, Department of Anaesthesiology, Zealand University Hospital, Køge, Denmark.
- Clinical Academic Group (CAG) Center for Endotheliomics, Department of Clinical Immunology, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark.
- Department of Anaesthesiology and Intensive Care, Copenhagen University Hospital-North Zealand, Hillerød, Denmark.
- Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
ORCID-Profile: Caroline Humble, Morten H Bestle, Pär I Johansson, Lone M Poulsen, Ole Mathiesen
Förderung
- Greater Copenhagen Health Science Partners
- Region Zealand Health Science Research Fund
- Clinical Academic Group (CAG) Center for Endotheliomics
- Intensive Care Symposium Hindsgavl
- A. P. Moller Foundation
- King Christian X Fund
- The Danish Society of Anaesthesiology and Intensive Care Medicine (DASAIM)
- Dansk Selskab for Anæstesiologi og Intensiv Medicin
Zitieren
APA
Humble, C., Schønemann-Lund, M., Bruun-Rasmussen, P., Bestle, M. H., Johansson, P. I., Poulsen, L. M., & Mathiesen, O. (2025). Pro‐ and Anti‐Inflammatory Responses and Clinical Outcomes in Critically Ill Patients With Endotheliopathy: A Cohort Study. Acta Anaesthesiologica Scandinavica. https://doi.org/10.1111/aas.70117
Vancouver
Humble C, Schønemann-Lund M, Bruun-Rasmussen P, Bestle MH, Johansson PI, Poulsen LM, et al. Pro‐ and Anti‐Inflammatory Responses and Clinical Outcomes in Critically Ill Patients With Endotheliopathy: A Cohort Study. Acta Anaesthesiologica Scandinavica. 2025. doi:10.1111/aas.70117
BibTeX
@article{Humble2025,
author = {Humble, Caroline and Schønemann-Lund, Martin and Bruun-Rasmussen, Peter and Bestle, Morten H and Johansson, Pär I and Poulsen, Lone M and Mathiesen, Ole},
title = {Pro‐ and Anti‐Inflammatory Responses and Clinical Outcomes in Critically Ill Patients With Endotheliopathy: A Cohort Study},
journal = {Acta Anaesthesiologica Scandinavica},
year = {2025},
doi = {10.1111/aas.70117}
}
EUVIMED